MergerAug 11, 2026, 04:14 PM
Sanara MedTech to be acquired by MIMEDX; Q2 Revenue up 9% to $28.1M
AI Summary
Sanara MedTech announced a transformational agreement to be acquired by MIMEDX, a leading provider in wound care, burn, and surgical sectors. This combination is expected to deepen distributor relationships and expand operating presence. Concurrently, Sanara reported Q2 2026 net revenue increased 9% to $28.1 million, with gross profit rising to $26.2 million. However, the company posted a net loss from continuing operations of $0.4 million for the quarter, compared to a net income in the prior year, while Adjusted EBITDA grew to $5.0 million.
Key Highlights
- Sanara MedTech announced a transformational agreement to be acquired by MIMEDX.
- Q2 2026 net revenue increased 9% to $28.1 million from $25.8 million in Q2 2025.
- Q2 2026 gross profit was $26.2 million, representing 93% of net revenue.
- Q2 2026 net loss from continuing operations was $0.4 million, or $0.05 per diluted share.
- Q2 2026 Adjusted EBITDA increased to $5.0 million from $4.7 million in Q2 2025.
- First six months of 2026 net revenue increased 14% to $55.9 million.
- Soft tissue repair product sales increased 11% to $25.2 million in Q2 2026.
- OsStic, a bone void filler, is on track for market introduction in Q1 2027.
Price Impact
More from SMTI